I recently came across a very important report that essentially says we are “still at it” with regard to measuring and improving the quality and safety of medical care, especially when it comes to medications.
Like so many other adults older than 60, I have had gastroesophageal reflux disease (GERD) for years, and I am taking a generic medication for the long-term. Refilling this medication quarterly, even at our university’s hospital-based pharmacy, is inconvenient, and I have to phone in the refill and personally appear to pick it up. There is no delivery option.
Mea culpa—I just didn’t get it! I had read multiple front-page articles in the Philadelphia Inquirer over months, but it just did not get past my “bad news” filter.
I’m confident that many of our readers are familiar with the Biotechnology Innovation Organization (BIO), “the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations."
Do you practice institutional racism? When I first heard this question, I was admittedly taken aback. It’s not a charge anyone would take lightly.
Despite having attended or participated in nearly 30 commencements in my role as a father and a Dean, I’ve never received an honorary degree until this year. I was thrilled to give the commencement address at Salus University in Philadelphia, PA, and receive an honorary degree for the first time.
What follows is an abbreviated version of my celebratory comments, with a special emphasis on the role of public accountability on the quality and safety of the care that we deliver.
Millennials now make up more than half of the white-collar workforce in our country. I have recently written elsewhere about their influence, and their potential to make a tremendous contribution in the near future.
As my physician wife (of the past 37 years) is fond of saying, “We are both rounding third base, heading to home” with regard to our long and fruitful careers as physician leaders. Therefore, when I am invited back to give a second plenary speech to any particular organization, it is an especially important opportunity.
KLAS holds an annual event that brings together vendors and customers on neutral territory to improve the quality of offerings in the healthcare marketplace. Admittedly, this is an unusual methodology, and I was asked to set the intellectual table for this important event that was focused on population health.
Page 2 of 9
Results 11 - 20 of 83
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME